Key features and details | |
Cat. No. | MABL-644 |
Name | Anti-CCL2 mAbs |
Clone No. | AFD- CNTO 888 (Carlumab) |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | inhibit, therapeutic, Block |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody specifically binds human CCL2 and does not cross react with mouse CCL2 or other human CC chemokines. It is reported that CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site. |
Alternative Name | MCP-1; MCP1; HC11; MCAF; C-C motif chemokine 2; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; Small-inducible cytokine A2 |
UniProt | P13500 |
Immunogen | The original antibody was generated by phage display using the Human Combinatorial Antibody Library (HuCAL GOLD). |
Application Notes | CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). |
Antibody First Published | Loberg et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. (2007); 9(7): 556–562.PMID:17710158 |
Note on publication | Describes the use of this antibody for retarding the tumor growth in prostrate cancer. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
